Search SciPol

Brought to you by
What it does 

HR 2038S 523, the Budgeting for Opioid Treatment Act, would establish a $0.01 / milligram "stewardship fee" for active opioid products sold by the manufacturer, producer, or importer of those products. This new revenue would be directed to the States to fund substance abuse initiatives, such as establishing new treatment facilities, hiring new mental health providers, or expanding access to long-term, residential treatment programs.